Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight

According to Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, positive Phase II findings could position PVX108 as an important future treatment option within the peanut allergy landscape.

GSK's Ozureprubart

Ozureprubart, also known as GSK6775388 or RPT904, is a long-acting monoclonal antibody designed to selectively target free human IgE, a key mediator of allergic reactions. The therapy is being investigated initially in food allergy and chronic spontaneous urticaria, with potential applications across other allergic inflammatory diseases.

Early clinical research in healthy volunteers demonstrated prolonged pharmacokinetic and pharmacodynamic activity compared with first-generation anti-IgE therapy. The candidate is currently undergoing Phase II evaluation in food allergy and could provide another mechanism-based approach to controlling allergic responses.

Download the report to understand the top emerging therapies in food allergy @ Food Allergy Clinical Trials - https://www.delveinsight.com/report-store/food-allergy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Future Outlook for the Food Allergy Market

The food allergy therapeutic landscape is moving beyond simple allergen avoidance toward targeted immune modulation, improved emergency treatment, and patient-friendly administration technologies. Patches, oral films, targeted biologics, and peptide-based immunotherapies represent distinct strategies that could broaden treatment choices and improve patient outcomes.

As these candidates advance through late-stage clinical development, their efficacy, safety, convenience, and potential to address unmet needs will determine their commercial success. With increasing awareness, continued investment, and several promising candidates approaching pivotal development milestones, the food allergy market is expected to remain an active area of innovation through 2036.

Source: Food Allergy Market Report

Food Allergy Market Insights, Epidemiology, and Market Forecast – 2036 report provides comprehensive insights into the disease landscape, historical and forecasted epidemiology, market trends, growth drivers, barriers, and leading companies involved in food allergy treatment development. The competitive landscape includes ARS Pharmaceuticals, Alfresa Pharma, Roche, Stallergenes Greer, DBV Technologies, Aquestive Therapeutics, Aravax, Siolta Therapeutics, GSK, Cue Biopharma, N-Fold, InnoUp Farma, Allergy Therapeutics, UKKO, Bryn Pharma, Poplar Therapeutics, Inimmune, Novartis, Intrommune Therapeutics, Regeneron Pharmaceuticals, Sanofi, Moonlight Therapeutics, Mabylon AG, Insignis Therapeutics, ALK-Abelló, Cambridge Allergy, Prota Therapeutics, and other market participants.

Conclusion

The food allergy market is entering a promising phase of transformation, supported by a growing pipeline of therapies designed to improve desensitization, immune modulation, and emergency treatment. Emerging approaches such as Viaskin, ANAPHYLM, remibrutinib, PVX108, and ozureprubart could expand treatment options and address important limitations associated with current therapies. With increasing disease awareness, advancing clinical programs, and rising demand for convenient and effective solutions, the food allergy market is expected to witness sustained growth through 2036.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Abhishek kumar

info@delveinsight.com